Lobaplatin (D-19466) in patients with advanced non-small-cell lung cancer: A trial of the Association for Medical Oncology (AIO) phase II study group;Lobaplatin (D-19466) bei Patienten mit fortgeschrittenem nichtkleinzelligem Bronchialkarzinom: Eine Untersuchung der Phase-II- Studiengruppe der Arbeitsgemeinschaft Internistische Onkologie (AIO)

Onkologie

Volumn 19, Issue 3, 1996, Pages 248-251

  Manegold, C ^a,e   Brings, P ^a   Gatzemeier, U ^a   Pawel, J ^b   Fiebig, H H ^c   Queisser W ^d   Edler, L ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemotherapy; Lobaplatin; Non small cell lung cancer; Phase II study

Indexed keywords

LOBAPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; VOMITING;

EID: 0029813379     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Voegeli R, Schumacher W, Engel J, Respondek J, Hilgard P: D-19466, a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncol 1990;116:439-442.
2. Einhorn LH, Donahue J: Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87:293-298.
3. Wilthaw E, Kroner T, Phase II study of cis-dichlochorodiammineplatinum (II) (NSC-119875, CACP) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 1976;60:55-60.
4. Soloway MS: Cis-diamminedichloroplatinum (II) (DDP) in advanced bladder cancer. J Urol 1978;120: 716-719.
5. Reed E, Kohn KW: Platinum analogues; in Chabner BA, Collins JM (eds): Cancer Chemotherapy. Philadelphia, Lippincott 1990, pp 465-490.
6. Canetta R, Bragman K, Smaldone L, Rosenzweig M: Carboplatin: Current status and future prospects. Cancer Treat Rev 19S8;15:17-32.
7. Harstrick A, Hapke G, Scharnofkse M, Reile D, Schmoll HJ; Poliwoda H: High activity of lobaplatin in cisplatin-sensitive and -resistant human carcinoma cell lines in vitro and in vivo. Am Assoc Cancer Res 1993;43:403(2401).
8. Clinical broschure for Investigates. Frankfurt, ASTA Medica Co., 1990.
9. Rebig HH, Berger DP, Mross K, Queißer W, Aulenbacher P, Hilgard P: Lobaplatin (D-19466): Preclinical drug profile and results of the phase I study. Ann Oncol 1992;3(suppl):143.
10. Rebig HH, Berger DP, Dengler WA, Wallbrecher E, Winterhalter BR: Combined in vitro/in vivo test procedure with human tumor xenografts; in Rebig HH, Berger DP (eds): Immunodeficient Mice in Oncology. Contrib Oncol. Basel, Karger, 1992, vol 42, pp 321-351.
11. Fiebig HH, Henß H, Mross K, Meyberg F, Aulenbacher P, Burk K, Queißer W: Phase I clinical trial of lobaplatin (D-19466) after intravenous bolus injection. Onkologie 1994;17:142-148.
12. Fiebig HH, Mross K; Henß H, Ludolph D, Meyberg F, Aulenbacher P, Queißer W: Phase I study of the new platin complex D-19466 on a single intermittent schedule. Am Assoc Cancer Res 1991;32:176.
13. Mross K, Meyberg F, Rebig HH, Hamm K, Hieber U, Aulenbacher P, Hossfeld DK: Pharmakokinetic and pharmacodynamic study with lobaplatin (D-19466), a new platinum complex, after bolus administration. Onkologie 1992;15:139-146.
14. Gietema JA, de Vries EGE, Guchelaar HY, Aulenbacher P, Willemse PHB, Mulder NH: Clinical dose-finding studies with a new platinum complex. Ann Oncol 1992;3(suppl)143;337.